All In Biotech

Drug Trial Radar · NCT00286793

Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC

An Open-label, Multicenter, Phase I/II Study of AT-101 in Combination With Docetaxel and Prednisone in Men With Hormone Refractory Prostate Cancer (HRPC)

Last checked: Nov 19, 2026Latest source record: Jun 29, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

76

Actual

Start

Feb 2006

Primary completion

Nov 2009

Study completion Nov 2009

Sponsor

Lead sponsor
Ascenta TherapeuticsIndustry
Sponsor type
Industry
First posted
Feb 6, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multicenter Phase I/II study to evaluate the safety and efficacy of AT-101 in combination with docetaxel and prednisone in men with hormone-refractory prostate cancer that are either chemotherapy naive or have received and progressed on a docetaxel containing regimen,

Conditions

  • Prostate Cancer

Interventions

  • AT-101Drug

    Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of AT-101 in combination with docetaxel and prednisoneTime frame: 12 months

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Hot Springs, Arkansas

  • Site not named

    Fort Meyers, Florida

  • Site not named

    Chicago, Illinois

  • Site not named

    Fridley, Minnesota

  • Site not named

    Albuquerque, New Mexico

  • Site not named

    Syracuse, New York

  • Site not named

    Wilmington, North Carolina

  • Site not named

    Portland, Oregon

  • Site not named

    Hilton Head Island, South Carolina

  • Site not named

    Germantown, Tennessee

  • Site not named

    Memphis, Tennessee

  • Site not named

    Nashville, Tennessee

  • Site not named

    Richardson, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.